Non-blocking modulation contributes to sodium channel inhibition by a covalently attached photoreactive riluzole analog

Peter Lukacs, Mátyás C. Földi, Luca Valánszki, Emilio Casanova, Beáta Biri-Kovács, L. Nyitray, A. Málnási-Csizmadia, A. Mike

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Sodium channel inhibitor drugs decrease pathological hyperactivity in various diseases including pain syndromes, myotonia, arrhythmias, nerve injuries and epilepsies. Inhibiting pathological but not physiological activity, however, is a major challenge in drug development. Sodium channel inhibitors exert their effects by a dual action: They obstruct ion flow ("block"), and they alter the energetics of channel opening and closing ("modulation"). Ideal drugs would be modulators without blocking effect, because modulation is inherently activity-dependent, therefore selective for pathological hyperactivity. Can block and modulation be separated? It has been difficult to tell, because the effect of modulation is obscured by conformation-dependent association/dissociation of the drug. To eliminate dynamic association/dissociation, we used a photoreactive riluzole analog which could be covalently bound to the channel; and found, unexpectedly, that drug-bound channels could still conduct ions, although with modulated gating. The finding that non-blocking modulation is possible, may open a novel avenue for drug development because non-blocking modulators could be more specific in treating hyperactivity-linked diseases.

Original languageEnglish
Article number8110
JournalScientific Reports
Volume8
Issue number1
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

Riluzole
Sodium Channels
Sodium Channel Blockers
Pharmaceutical Preparations
Myotonia
Ions
Inhibition (Psychology)
Cardiac Arrhythmias
Epilepsy
Pain
Wounds and Injuries

ASJC Scopus subject areas

  • General

Cite this

Non-blocking modulation contributes to sodium channel inhibition by a covalently attached photoreactive riluzole analog. / Lukacs, Peter; Földi, Mátyás C.; Valánszki, Luca; Casanova, Emilio; Biri-Kovács, Beáta; Nyitray, L.; Málnási-Csizmadia, A.; Mike, A.

In: Scientific Reports, Vol. 8, No. 1, 8110, 01.12.2018.

Research output: Contribution to journalArticle

Lukacs, Peter ; Földi, Mátyás C. ; Valánszki, Luca ; Casanova, Emilio ; Biri-Kovács, Beáta ; Nyitray, L. ; Málnási-Csizmadia, A. ; Mike, A. / Non-blocking modulation contributes to sodium channel inhibition by a covalently attached photoreactive riluzole analog. In: Scientific Reports. 2018 ; Vol. 8, No. 1.
@article{8f58d2fdd56d418da1afb115b363720f,
title = "Non-blocking modulation contributes to sodium channel inhibition by a covalently attached photoreactive riluzole analog",
abstract = "Sodium channel inhibitor drugs decrease pathological hyperactivity in various diseases including pain syndromes, myotonia, arrhythmias, nerve injuries and epilepsies. Inhibiting pathological but not physiological activity, however, is a major challenge in drug development. Sodium channel inhibitors exert their effects by a dual action: They obstruct ion flow ({"}block{"}), and they alter the energetics of channel opening and closing ({"}modulation{"}). Ideal drugs would be modulators without blocking effect, because modulation is inherently activity-dependent, therefore selective for pathological hyperactivity. Can block and modulation be separated? It has been difficult to tell, because the effect of modulation is obscured by conformation-dependent association/dissociation of the drug. To eliminate dynamic association/dissociation, we used a photoreactive riluzole analog which could be covalently bound to the channel; and found, unexpectedly, that drug-bound channels could still conduct ions, although with modulated gating. The finding that non-blocking modulation is possible, may open a novel avenue for drug development because non-blocking modulators could be more specific in treating hyperactivity-linked diseases.",
author = "Peter Lukacs and F{\"o}ldi, {M{\'a}ty{\'a}s C.} and Luca Val{\'a}nszki and Emilio Casanova and Be{\'a}ta Biri-Kov{\'a}cs and L. Nyitray and A. M{\'a}ln{\'a}si-Csizmadia and A. Mike",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-26444-y",
language = "English",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Non-blocking modulation contributes to sodium channel inhibition by a covalently attached photoreactive riluzole analog

AU - Lukacs, Peter

AU - Földi, Mátyás C.

AU - Valánszki, Luca

AU - Casanova, Emilio

AU - Biri-Kovács, Beáta

AU - Nyitray, L.

AU - Málnási-Csizmadia, A.

AU - Mike, A.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Sodium channel inhibitor drugs decrease pathological hyperactivity in various diseases including pain syndromes, myotonia, arrhythmias, nerve injuries and epilepsies. Inhibiting pathological but not physiological activity, however, is a major challenge in drug development. Sodium channel inhibitors exert their effects by a dual action: They obstruct ion flow ("block"), and they alter the energetics of channel opening and closing ("modulation"). Ideal drugs would be modulators without blocking effect, because modulation is inherently activity-dependent, therefore selective for pathological hyperactivity. Can block and modulation be separated? It has been difficult to tell, because the effect of modulation is obscured by conformation-dependent association/dissociation of the drug. To eliminate dynamic association/dissociation, we used a photoreactive riluzole analog which could be covalently bound to the channel; and found, unexpectedly, that drug-bound channels could still conduct ions, although with modulated gating. The finding that non-blocking modulation is possible, may open a novel avenue for drug development because non-blocking modulators could be more specific in treating hyperactivity-linked diseases.

AB - Sodium channel inhibitor drugs decrease pathological hyperactivity in various diseases including pain syndromes, myotonia, arrhythmias, nerve injuries and epilepsies. Inhibiting pathological but not physiological activity, however, is a major challenge in drug development. Sodium channel inhibitors exert their effects by a dual action: They obstruct ion flow ("block"), and they alter the energetics of channel opening and closing ("modulation"). Ideal drugs would be modulators without blocking effect, because modulation is inherently activity-dependent, therefore selective for pathological hyperactivity. Can block and modulation be separated? It has been difficult to tell, because the effect of modulation is obscured by conformation-dependent association/dissociation of the drug. To eliminate dynamic association/dissociation, we used a photoreactive riluzole analog which could be covalently bound to the channel; and found, unexpectedly, that drug-bound channels could still conduct ions, although with modulated gating. The finding that non-blocking modulation is possible, may open a novel avenue for drug development because non-blocking modulators could be more specific in treating hyperactivity-linked diseases.

UR - http://www.scopus.com/inward/record.url?scp=85047642785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047642785&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-26444-y

DO - 10.1038/s41598-018-26444-y

M3 - Article

AN - SCOPUS:85047642785

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 8110

ER -